KTRA Insider Trading Activity and SEC Form 4 Filings
KTRA insider trading summary
No open-market insider purchases or sales of Kintara Therapeutics, Inc. (KTRA) have been reported on SEC Form 4 in the past 12 months.
Latest KTRA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 15, 2022 | Robert E. Hoffman | President and CEO | Buy | $26K (55,000 @ $0.47) |
| Dec 8, 2021 | Anthony Scott Praill | Chief Financial Officer | Buy | $19K (28,700 @ $0.68) |
| Dec 7, 2021 | Saiid Zarrabian | Head of Strategic Partnerships | Buy | $24K (38,109 @ $0.64) |
| Dec 6, 2021 | Saiid Zarrabian | Head of Strategic Partnerships | Buy | $7K (11,891 @ $0.59) |
| Nov 22, 2021 | Laura L. Johnson | Director | Buy | $2K (3,000 @ $0.74) |
| Aug 19, 2020 | John Liatos | SVP, Business Development | Buy | $0 (196,750 @ $0.00) |
| Aug 19, 2020 | Keith Murphy | Director | Buy | $0 (181,010 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.